uniQure is set to raise around $75M through its public offering of 4,411,764 shares at $17 each, highlighting the strong interest in biotechnology.
This funding comes shortly after uniQure's agreement with the FDA on an Accelerated Approval pathway for AMT-130, targeting Huntington's disease clinical trials.
The company's innovative gene therapy approach focuses on severe genetic diseases, with ongoing studies evaluating safety and efficacy of AMT-130 for Huntington's disease.
As part of the offering, underwriters have a 30-day option to purchase additional shares, indicating confidence in uniQure's growth potential.
Collection
[
|
...
]